DEXCOM, INC. Operating Lease Cost
DEXCOM, INC. (DXCM) reported Operating Lease Cost of $21.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-12
- DEXCOM, INC. operating lease, cost for the quarter ending 2019-12-31 was $3.80M.
- DEXCOM, INC. operating lease, cost for the quarter ending 2019-09-30 was $2.80M.
- DEXCOM, INC. operating lease, cost for the quarter ending 2019-06-30 was $3.10M.
- DEXCOM, INC. operating lease, cost for the quarter ending 2019-03-31 was $2.50M.
- DEXCOM, INC. operating lease, cost for fiscal 2025 was $21.50M, a 4.02% decline from fiscal 2024.
- DEXCOM, INC. operating lease, cost for fiscal 2024 was $22.40M, a 2.18% decline from fiscal 2023.
- DEXCOM, INC. operating lease, cost for fiscal 2023 was $22.90M, a 1.33% increase from fiscal 2022.
- DEXCOM, INC. operating lease, cost for fiscal 2022 was $22.60M, a 3.00% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $21.50M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $22.40M 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $22.90M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $22.60M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $23.30M 10-K · filed 2024-02-08 | |||
| 2020-12-31 | $18.40M 10-K · filed 2023-02-09 | |||
| 2019-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $6.60M derived: sum of 2 quarters · filed 2022-02-14 | $9.70M derived: sum of 3 quarters · filed 2022-02-14 | $12.20M 10-K · filed 2022-02-14 |
| 2019-09-30 | $2.80M 10-Q · filed 2019-11-06 | $5.90M derived: sum of 2 quarters · filed 2019-11-06 | $8.40M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $3.10M 10-Q · filed 2019-07-31 | $5.60M 10-Q · filed 2019-07-31 | ||
| 2019-03-31 | $2.50M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |